Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchBamlanivimab/etesevimabBamlaniv../e.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Real World Outcomes of Cancer Patients With SARS-CoV-2 Infection Receiving Monoclonal Antibodies

Wilden et al., Journal of the National Comprehensive Cancer Network, doi:10.6004/jnccn.2021.7309
Mar 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Hospitalization 51% Improvement Relative Risk Bamlanivimab/e..  Wilden et al.  EARLY TREATMENT Is early treatment with bamlanivimab/etesevimab beneficial for COVID-19? Retrospective study in the USA (December 2020 - July 2021) Lower hospitalization with bamlanivimab/etesevimab (not stat. sig., p=0.06) c19early.org Wilden et al., J. the National Compreh.., Mar 2022 Favorsbamlanivimab/e.. Favorscontrol 0 0.5 1 1.5 2+
22nd treatment shown to reduce risk in May 2021, now with p = 0.00036 from 21 studies, recognized in 7 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
Retrospective 395 patients in the USA receiving casirivimab/imdevimab or bamlanivimab, showing lower risk of hospitalization with treatment, statistically significant for casirivimab/imdevimab.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron1-5.
Although the 51% lower hospitalization is not statistically significant, it is consistent with the significant 42% lower hospitalization [30‑53%] from meta analysis of the 15 hospitalization results to date.
Study covers bamlanivimab/etesevimab and casirivimab/imdevimab.
risk of hospitalization, 51.0% lower, OR 0.49, p = 0.06, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wilden et al., 31 Mar 2022, retrospective, USA, peer-reviewed, 9 authors, study period December 2020 - July 2021.
This PaperBamlaniv../e..All
{ 'indexed': {'date-parts': [[2022, 4, 4]], 'date-time': '2022-04-04T00:56:40Z', 'timestamp': 1649033800757}, 'reference-count': 0, 'publisher': 'Harborside Press, LLC', 'issue': '3.5', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': [], 'published-print': {'date-parts': [[2022, 3, 31]]}, 'DOI': '10.6004/jnccn.2021.7309', 'type': 'journal-article', 'created': {'date-parts': [[2022, 3, 31]], 'date-time': '2022-03-31T11:49:36Z', 'timestamp': 1648727376000}, 'page': 'HSR22-178', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ 'HSR22-178: Real World Outcomes of Cancer Patients With SARS-CoV-2 Infection Receiving ' 'Monoclonal Antibodies'], 'prefix': '10.6004', 'volume': '20', 'author': [ { 'given': 'Alexa', 'family': 'Wilden', 'sequence': 'first', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}, { 'given': 'Aishwarya', 'family': 'Sannareddy', 'sequence': 'additional', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}, { 'given': 'Hetal', 'family': 'Patel', 'sequence': 'additional', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}, { 'given': 'Shraddha', 'family': 'Kansagra', 'sequence': 'additional', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}, { 'given': 'Gurbakhash', 'family': 'Kaur', 'sequence': 'additional', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}, { 'given': 'Praveen', 'family': 'Ramakrishnan', 'sequence': 'additional', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}, { 'given': 'Prapti', 'family': 'Patel', 'sequence': 'additional', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}, { 'given': 'Ansh', 'family': 'Mehta', 'sequence': 'additional', 'affiliation': [{'name': '2 Jacobi Medical Center, Bronx, NY'}]}, { 'given': 'Ankit', 'family': 'Kansagra', 'sequence': 'additional', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}], 'member': '4047', 'container-title': ['Journal of the National Comprehensive Cancer Network'], 'original-title': [], 'link': [ { 'URL': 'https://jnccn.org/view/journals/jnccn/20/3.5/article-pHSR22-178.xml', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://jnccn.org/view/journals/jnccn/20/3.5/article-pHSR22-178.xml', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 3, 31]], 'date-time': '2022-03-31T11:50:05Z', 'timestamp': 1648727405000}, 'score': 1, 'resource': {'primary': {'URL': 'https://jnccn.org/view/journals/jnccn/20/3.5/article-pHSR22-178.xml'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 3, 31]]}, 'references-count': 0, 'journal-issue': {'issue': '3.5'}, 'URL': 'http://dx.doi.org/10.6004/jnccn.2021.7309', 'relation': {}, 'ISSN': ['1540-1405', '1540-1413'], 'issn-type': [{'value': '1540-1405', 'type': 'print'}, {'value': '1540-1413', 'type': 'electronic'}], 'subject': ['Oncology'], 'published': {'date-parts': [[2022, 3, 31]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit